Oncodesign acquires human colorectal cancer models
With this acquisition, Oncodesign’s clients are now eligible to access the entire collection to assess therapeutic compounds in house or to carry out preclinical studies with Oncodesign. The
China-based IMPACT Therapeutics and Pharmanovia have entered an exclusive licensing deal worth up to €423.5m ($488.3m), giving Pharmanovia rights to manufacture, develop, and commercialise senaparib in 66 countries.